282 related articles for article (PubMed ID: 19131041)
21. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
Zhu BT
Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
[TBL] [Abstract][Full Text] [Related]
22. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.
Qin Z; Hu D; Han S; Reaney SH; Di Monte DA; Fink AL
J Biol Chem; 2007 Feb; 282(8):5862-70. PubMed ID: 17189262
[TBL] [Abstract][Full Text] [Related]
23. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
Michel PP; Ruberg M; Hirsch E
Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
[TBL] [Abstract][Full Text] [Related]
25. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
26. Does cellular iron dysregulation play a causative role in Parkinson's disease?
Kaur D; Andersen J
Ageing Res Rev; 2004 Jul; 3(3):327-43. PubMed ID: 15231240
[TBL] [Abstract][Full Text] [Related]
27. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
28. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
29. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells.
Parihar MS; Parihar A; Fujita M; Hashimoto M; Ghafourifar P
Int J Biochem Cell Biol; 2009 Oct; 41(10):2015-24. PubMed ID: 19460457
[TBL] [Abstract][Full Text] [Related]
30. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
Lashuel HA; Hirling H
ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
[TBL] [Abstract][Full Text] [Related]
31. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
Häbig K; Walter M; Stappert H; Riess O; Bonin M
Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
[TBL] [Abstract][Full Text] [Related]
32. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
[TBL] [Abstract][Full Text] [Related]
33. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
34. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
[TBL] [Abstract][Full Text] [Related]
35. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
Kao SY
Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
[TBL] [Abstract][Full Text] [Related]
36. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
[TBL] [Abstract][Full Text] [Related]
37. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
[TBL] [Abstract][Full Text] [Related]
38. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal.
Zhang S; Eitan E; Wu TY; Mattson MP
Neurobiol Aging; 2018 Jan; 61():52-65. PubMed ID: 29035751
[TBL] [Abstract][Full Text] [Related]
39. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders.
Ben-Shachar D; Zuk R; Gazawi H; Ljubuncic P
Biochem Pharmacol; 2004 May; 67(10):1965-74. PubMed ID: 15130772
[TBL] [Abstract][Full Text] [Related]
40. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
